{
    "clinical_study": {
        "@rank": "137998", 
        "arm_group": [
            {
                "arm_group_label": "Arm 1", 
                "arm_group_type": "Experimental", 
                "description": "BI 655066 s.c."
            }, 
            {
                "arm_group_label": "Arm 2", 
                "arm_group_type": "Experimental", 
                "description": "BI 655066 s.c."
            }, 
            {
                "arm_group_label": "Arm 3", 
                "arm_group_type": "Experimental", 
                "description": "BI 655066 s.c."
            }, 
            {
                "arm_group_label": "Arm 4", 
                "arm_group_type": "Active Comparator", 
                "description": "Ustekinumab s.c."
            }
        ], 
        "brief_summary": {
            "textblock": "The overall purpose of this trial is to assess clinical efficacy and safety of different\n      subcutaneous doses of BI 655066 in adult patients with chronic plaque psoriasis in order to\n      select doses for further clinical trials."
        }, 
        "brief_title": "BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Psoriasis", 
        "condition_browse": {
            "mesh_term": "Psoriasis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Body Mass Index (BMI) = 18.5 and < 40 kg/m\u00b2\n\n          -  Patients with stable moderate to severe chronic plaque-type psoriasis with or without\n             psoriatic arthritis involving >/= 10% body surface area, with disease severity PASI\n             >/= 12 and sPGA score of moderate and above (score of at least 3) at screening visit\n             and visit 2 (randomisation), as assessed by the investigator\n\n          -  Psoriasis disease duration of at least 6 months prior to screening, as assessed by\n             the investigator\n\n          -  Patients must be candidates for systemic psoriasis treatment or phototherapy, as\n             assessed by the investigator\n\n          -  Patients must be suitable candidates for ustekinumab (Stelara\u00ae) therapy as given in\n             the local labelling\n\n          -  Patient must give informed consent and sign an approved consent form prior to any\n             study procedures in accordance with GCP and local legislation\n\n        Exclusion criteria:\n\n          -  Patients with guttate, erythrodermic, or pustular psoriasis and patients with\n             drug-induced psoriasis, as diagnosed by the investigator\n\n          -  Evidence of current or previous clinically significant disease, medical condition\n             other than psoriasis, or finding of the medical examination (including vital signs\n             and ECG), that in the opinion of the investigator, would compromise the safety of the\n             patient or the quality of the data. This criterion provides an opportunity for the\n             investigator to exclude patients based on clinical judgment, even if other\n             eligibility criteria are satisfied. (Psoriatic arthritis is not considered an\n             exclusion criterion)\n\n          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,\n             immunological or hormonal disorders, diseases of the central nervous system (such as\n             epilepsy) or psychiatric disorders or neurological disorders, or history of\n             orthostatic hypotension, fainting spells or blackouts, that in the investigator's\n             judgement, could jeopardize the safe conduct of the study.\n\n          -  Clinically important acute or chronic infections including hepatitis, HIV and\n             tuberculosis (including latent tuberculosis), or a positive interferon gamma release\n             assay (IGRA) testing for tuberculosis\n\n          -  Have had a live vaccination >/= 12 weeks prior to randomisation (visit 2). Patients\n             must agree not to receive a live vaccination during the study. No BCG vaccines should\n             be given for one year prior to randomisation (visit 2), during the study and for one\n             year after last administration of study drug (according to the Stelara\u00ae SPC).\n\n          -  History of clinically significant hypersensitivity to a systemically administered\n             biologic agent or its excipients\n\n          -  History of malignancy in the past 5 years or suspicion of active malignant disease\n             except treated cutaneous squamous cell or basal cell carcinoma\n\n          -  Has received any therapeutic agent directly targeted to IL-12, IL-23 (including\n             ustekinumab (Stelara\u00ae)\n\n          -  Use of biologic agents within 12 weeks (infliximab, etanercept, adalimumab, other\n             biologics) prior to treatment, systemic anti-psoriatic medications or phototherapy\n             within 4 weeks prior to treatment, or topical anti-psoriasis medications within 2\n             weeks prior to treatment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "160", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 3, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02054481", 
            "org_study_id": "1311.2", 
            "secondary_id": "2012-004384-48"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm 2", 
                "description": "Medium dose", 
                "intervention_name": "BI 655066", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm 3", 
                "description": "High dose", 
                "intervention_name": "BI 655066", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm 4", 
                "intervention_name": "Ustekinumab", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm 1", 
                "description": "Low dose", 
                "intervention_name": "BI 655066", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Antibodies, Monoclonal"
        }, 
        "lastchanged_date": "May 28, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "1311.2.10010 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Port Orange", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "1311.2.10013 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Arlington Hts", 
                        "country": "United States", 
                        "state": "Illinois"
                    }, 
                    "name": "1311.2.10003 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Normal", 
                        "country": "United States", 
                        "state": "Illinois"
                    }, 
                    "name": "1311.2.10008 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bay City", 
                        "country": "United States", 
                        "state": "Michigan"
                    }, 
                    "name": "1311.2.10002 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fridley", 
                        "country": "United States", 
                        "state": "Minnesota"
                    }, 
                    "name": "1311.2.10004 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "East Windsor", 
                        "country": "United States", 
                        "state": "New Jersey"
                    }, 
                    "name": "1311.2.10001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Verona", 
                        "country": "United States", 
                        "state": "New Jersey"
                    }, 
                    "name": "1311.2.10009 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Raleigh", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }, 
                    "name": "1311.2.10007 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon"
                    }, 
                    "name": "1311.2.10005 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas"
                    }, 
                    "name": "1311.2.10006 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas"
                    }, 
                    "name": "1311.2.10011 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Spokane", 
                        "country": "United States", 
                        "state": "Washington"
                    }, 
                    "name": "1311.2.10012 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Markham", 
                        "country": "Canada", 
                        "state": "Ontario"
                    }, 
                    "name": "1311.2.20002 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Waterloo", 
                        "country": "Canada", 
                        "state": "Ontario"
                    }, 
                    "name": "1311.2.20003 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sainte-Foy", 
                        "country": "Canada", 
                        "state": "Quebec"
                    }, 
                    "name": "1311.2.20004 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Peterborough", 
                        "country": "Canada"
                    }, 
                    "name": "1311.2.20005 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Helsinki", 
                        "country": "Finland"
                    }, 
                    "name": "1311.2.35802 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Turku", 
                        "country": "Finland"
                    }, 
                    "name": "1311.2.35801 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Marseille", 
                        "country": "France"
                    }, 
                    "name": "1311.2.33005 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nice", 
                        "country": "France"
                    }, 
                    "name": "1311.2.33002 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France"
                    }, 
                    "name": "1311.2.33001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pessac", 
                        "country": "France"
                    }, 
                    "name": "1311.2.33004 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rouen", 
                        "country": "France"
                    }, 
                    "name": "1311.2.33003 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toulouse", 
                        "country": "France"
                    }, 
                    "name": "1311.2.33006 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany"
                    }, 
                    "name": "1311.2.49001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dresden", 
                        "country": "Germany"
                    }, 
                    "name": "1311.2.49003 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "L\u00fcbeck", 
                        "country": "Germany"
                    }, 
                    "name": "1311.2.49005 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mainz", 
                        "country": "Germany"
                    }, 
                    "name": "1311.2.49002 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "M\u00fcnster", 
                        "country": "Germany"
                    }, 
                    "name": "1311.2.49004 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oslo", 
                        "country": "Norway"
                    }, 
                    "name": "1311.2.47001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "\u00c5lesund", 
                        "country": "Norway"
                    }, 
                    "name": "1311.2.47002 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Malm\u00f6", 
                        "country": "Sweden"
                    }, 
                    "name": "1311.2.46002 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stockholm", 
                        "country": "Sweden"
                    }, 
                    "name": "1311.2.46001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada", 
                "Finland", 
                "France", 
                "Germany", 
                "Norway", 
                "Sweden"
            ]
        }, 
        "number_of_arms": "4", 
        "official_title": "A 48 Weeks Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Moderate to Severe Chronic Plaque Psoriasis (Randomised, Dose-ranging, Active-comparator-controlled (Ustekinumab), Double-blind Within Dose Groups of BI 655066)", 
        "overall_contact": {
            "email": "clintriage.rdg@boehringer-ingelheim.com", 
            "last_name": "Boehringer Ingelheim Call Center", 
            "phone": "1-800-243-0127"
        }, 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Canada: Health Canada", 
                "Finland: Finnish Medicines Agency", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Germany: Paul-Ehrlich-Institut", 
                "Norway: Norwegian Medicines Agency", 
                "Sweden: Medical Products Agency", 
                "United States: Food and Drug Administration"
            ]
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Achievement of >/= 90% reduction from baseline PASI score (PASI90) at week 12", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02054481"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Achievement of >/= 50% reduction from baseline in PASI score (PASI50) at week 12", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Achievement of PASI90 at week 24", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Achievement of sPGA clear or almost clear at week 12", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Achievement of >/=75% reduction from baseline in PASI score (PASI75) at week 12 and 24", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Achievement of 100% reduction from baseline in PASI score (PASI100) at week 12", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Percentage of PASI reduction from baseline at week 12", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Time to loss of PASI50 response. This endpoint is calculated from the first treatment to first < 50% reduction of PASI score compared with baseline after the response has been achieved", 
                "safety_issue": "No", 
                "time_frame": "up to 48 weeks"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}